[Corrections] Correction to Lancet Oncol 2017; 18: 1061–75

Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol 2017; 18: 1061–75—In this Article, the following sentence about the safety results in the findings section of the Summary should have read: "Commonly reported treatment-related adverse events were diarrhoea (41 [16%]), fatigue (37 [15%]), elevated aspartate aminotransferase (33 [13%]), and elevated alanine aminotransferase (24 [10%])." The incidence of serious febrile neutropenia in the Summary findings and in the main Results (fourth paragraph, first sentence) should have been reported as 78 (31%).

https://ift.tt/2MxdnEC